Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity.
about
Extra-mammary findings detected on breast magnetic resonance imaging: a pictorial essayPredicting skeletal complications in metastatic breast cancer raises challenges.Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey.Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis surveyTreatment outcome and prognostic factors for patients with bone-only metastases of breast cancer: a single-institution retrospective analysisPossible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features-An exploratory analysis of placebo-controlled trialsIncidence, consequences and treatment of bone metastases in breast cancer patients-Experience from a single cancer centre.Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents.Cost analysis of skeletal-related events in Spanish patients with bone metastases from solid tumoursUnderstanding tumor-stroma interplays for targeted therapies by armed mesenchymal stromal progenitors: the Mesenkillers.MRI of metastasis-permissive microenvironments.Breast cancer and bone metastases: the association of axial skeleton MRI findings with skeletal-related events and survival.A short account of metastatic bone disease.Prevalence and risk factors of bone metastasis and skeletal related events in patients with primary breast cancer in Japan.Human breast cancer bone metastasis in vitro and in vivo: a novel 3D model system for studies of tumour cell-bone cell interactions.Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries.
P2860
Q33929277-0D63C1F0-B6A4-4AA9-8163-FDAA9AFFBD78Q34247639-3280692C-E373-4213-83F6-FF63A68B81E8Q35034474-D496A937-82C4-4517-8370-DB073C26E7FCQ35080143-F6061B69-DCBB-48B8-8F89-C6CBAD87500EQ35584408-4C67F210-C223-4D5C-9D31-CC6DB6166D5AQ36491479-83D92346-CC15-477A-A681-C0EFA38F4A90Q36491533-4FEA26A7-339E-4B0A-93BC-EDFFA773436EQ36788277-0DFA6538-68ED-4843-B0B2-953D456C6FD2Q37583093-073525AA-098A-4511-A390-0F2297F2CE99Q37948053-5325DF94-5BF3-46F2-B2ED-0A0DA61FC6A7Q37951603-C849D4C9-A1C7-41D5-8CC6-39C7195219AFQ38227713-94364155-8B65-4CC9-A64D-1E01B270C8C5Q38255403-9E4FE50B-2090-48E6-A9C1-97DA7A735233Q48125689-7ED0CD9E-9C45-488A-BB3B-C231045E8085Q53399441-2A8E2478-28D1-425A-B99B-933F6FC7C98FQ55114445-D5FBA09D-018A-48F4-9165-6F18139C1ED2
P2860
Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Natural history of malignant b ...... to measure skeletal morbidity.
@ast
Natural history of malignant b ...... to measure skeletal morbidity.
@en
type
label
Natural history of malignant b ...... to measure skeletal morbidity.
@ast
Natural history of malignant b ...... to measure skeletal morbidity.
@en
prefLabel
Natural history of malignant b ...... to measure skeletal morbidity.
@ast
Natural history of malignant b ...... to measure skeletal morbidity.
@en
P2093
P2860
P356
P1433
P1476
Natural history of malignant b ...... to measure skeletal morbidity.
@en
P2093
Allan Lipton
Evangelos Terpos
Matthew R Smith
Pierre P Major
Richard J Cook
Robert E Coleman
P2860
P2888
P356
10.1186/1471-2407-9-272
P407
P577
2009-08-06T00:00:00Z
P5875
P6179
1004247674